<DOC>
	<DOCNO>NCT03016143</DOCNO>
	<brief_summary>The study single centre , phase II , double-blind , randomize , comparative trial explore immunogenicity safety single dose allantoic split inactivate seasonal influenza vaccine VAXIGRIP vacccine healthy adult two age group ( person 18 60 year age old 60 year ) .</brief_summary>
	<brief_title>Immunogenicity Safety Study Allantoic Split Inactivated Seasonal Influenza Vaccine ( VSI )</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>volunteer ( men woman ) age 18 year old . Literate willing provide write informed consent . A sign informed consent . Available anamnaze volunteer allergic reaction . Allergic reaction chicken protein , precede vaccination . Acute illness fever ( 37.0 C ) . Vaccination influenza 2015/2016 season . Current recent ( within two week enrollment ) acute respiratory illness without fever . Hypersensitivity previous administration vaccine . History chronic alcohol abuse and/or illegal drug use . Any clinically significant abnormal laboratory finding . A positive pregnancy test woman childbearing potential . Administration immunosuppressive drug immune modify drug within 4 week prior study enrollment . Acute chronic clinically significant pulmonary disease , cardiovascular disease , gastrointestinal disease , liver disease , neurological illness , liver disease , blood disease , skin disorder , endocrine disorder , neurological illness psychiatric disorder determine medical history , physical examination clinical laboratory screening test , opinion investigator , might interfere study objective . History leukemia blood solid organ cancer . Receipt antiviral , antibiotic , immunoglobulin blood product within 4 week prior study enrollment plan receipt product period subject participation study . Participation another clinical trial within previous three month plan enrollment trial period study . Subjects , opinion investigator , significantly increase risk noncooperation requirement study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>phase II</keyword>
	<keyword>split</keyword>
	<keyword>vaccine</keyword>
</DOC>